English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background HEPLISAV-B® [hepatitis B vaccine (recombinant), adjuvanted] uses a cytidine phospho-guanosine (CpG) oligonucleotide or “1018,” a Toll-like receptor 9 agonist, as an adjuvant. Engerix-B® [hepatitis B vaccine (recombinant)], as well as other hepatitis B vaccines, use alum. HEPLISAV-B, a 2-dose vaccine given at Weeks 0 and 4, was recently approved for use in adults ≥18 years for the prevention of hepatitis B. Approval of HEPLISAV-B was based on three pivotal phase 3 noninferiority trials, comparing it with Engerix-B, a 3-dose vaccine given at Day 0, Day 30, and 6 months. Immunogenicity and safety results for these trials, HBV-10, HBV-16 and HBV-23, have been published previously; the safety of HEPLISAV-B was generally similar to Engerix-B. Methods The 3 randomized trials were observer-blinded and collectively included subjects aged 18–70 years. Immunogenicity analysis based on antibody against hepatitis B surface antigen (anti-HBs) levels were based on the per-protocol analysis. Presented here are reverse cumulative frequency plots of anti-HBs serum concentrations for the 3 trials. Results Across the trials, reverse cumulative frequency plots of anti-HBs concentrations showed a higher proportion (>90%) of HEPLISAV-B subjects developed a seroprotective antibody level (anti-HBs levels ≥10 mIU/mL) compared with Engerix-B subjects (80% to ~90%). A higher proportion of HEPLISAV-B subjects had anti-HBs levels between 10 mIU/mL and 1,000 mIU/mL. While a higher proportion of Engerix-B subjects had anti-HBs levels >1,000 mIU/mL, a significantly higher proportion of Engerix-B subjects did not develop seroprotective antibody levels. The response curves indicate a more consistent immune response with a higher percentage of subjects achieving seroprotection with less variability for HEPLISAV-B compared with Engerix-B, which showed a more variable response and fewer subjects achieving seroprotection. Conclusion HEPLISAV-B, using a CpG adjuvant, results in a higher percentage of persons achieving seroprotection and produces a more uniform and consistent induction of protective antibody levels than Engerix-B, an alum-adjuvanted vaccine. Disclosures R. N. Hyer, Dynavax Technologies Corporation: Employee and Shareholder, Salary and Stock options. R. Janssen, Dynavax Technologies Corporation: Employee and Shareholder, Salary and Stock options.

open forum infectious diseases

2287. Recently Approved HEPLISAV-B(R) [Hepatitis B Vaccine (Recombinant), Adjuvanted] Shows a Higher Proportion of Subjects Achieving Seroprotection With a More Consistent Immune Response Compared With Engerix-B(R) [Hepatitis B Vaccine (Recombinant)] in Three Comparative Trials